ArticleInternational journal of endocrinology2026
Association Between C-Reactive Protein-Triglyceride Glucose Index and All-Cause and Cardiovascular Mortality Across Cardiovascular-Kidney-Metabolic Syndrome Stages 0-4.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between C-Reactive Protein-Triglyceride Glucose Index and All-Cause and Cardiovascular Mortality Across Cardiovascular-Kidney-Metabolic Syndrome Stages 0-4.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Advanced cardiovascular-kidney-metabolic (CKM) syndrome corresponds to an elevated risk of mortality. The C-reactive protein-triglyceride glucose index (CTI) reflects both insulin resistance and inflammation, processes that are crucial to CKM progression. However, it remains uncertain whether CTI is linked to mortality risk and how this relationship may vary across different CKM progression stages. Methods: A total of 8314 participants were drawn from American adults. Participants were then grouped by advanced CKM stages. CTI was calculated as 0.412 × Ln (CRP [mg/L]) + Ln (TG [mg/dl] × FBG [mg/dl])/2. The endpoints focused on all-cause and cardiovascular mortality. Associations of CTI with advanced CKM stages and mortality were examined using logistic and Cox regression models, respectively. Results: The highest CTI quartile (Q4) exhibited a markedly greater prevalence of advanced CKM stages relative to Q1 ( Conclusion: Higher CTI levels were accompanied by a greater prevalence of advanced CKM stages and were associated with increased risks of all-cause and cardiovascular mortality across CKM stages. CTI may provide complementary information for mortality-risk assessment although further validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.